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without any clinical evidence of active tuberculosis. The
total cellular immunity of HIV-positive individuals with
latent tuberculosis co-infection wasn’t impaired, while the
speciﬁc immune response to MTB in them was signiﬁcantly
increased. Either the total cellular immunity or the speciﬁc
immune response to MTB in those with active tuberculosis
co-infection was seriously destructed.
Fig. 1. The ESAT-6 speciﬁc spot-forming cells of T SPOT-
TB assay in different population groups. Group HIV+TB-:
patients with HIV infection only, no MTB co-infection, n = 22;
Group HIV+LTB: patients with HIV infection and latent
tuberculosis co-infection, n = 46; Group HIV+TB: patients
with HIV infection and active tuberculosis co-infection,
n = 32. SFCs: spot-forming cells. The short transverse line
represents mean of SFCs in different population groups.
HIV+TB-: 0 SFCs/106 PBMC; HIV+LTB: 92 SFCs/106 PBMC;
HIV+TB: 31 SFCs/106 PBMC.
Fig. 2. The CFP-10 speciﬁc spot-forming cells of T SPOT-
TB assay in different population groups. Group HIV+TB-:
patients with HIV infection only, no MTB co-infection, n = 22;
Group HIV+LTB: patients with HIV infection and latent
tuberculosis co-infection, n = 46; Group HIV+TB: patients
with HIV infection and active tuberculosis co-infection,
n = 32. SFCs: spot-forming cells. The short transverse line
represents mean of SFCs in different population groups.
HIV+TB-: 1 SFCs/106 PBMC; HIV+LTB: 109 SFCs/106 PBMC;
HIV+TB: 82 SFCs/106 PBMC.
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Hepatitis B virus infection is a major global public health
problem but it is preventable with safe and effective vaccine
which has available for decade. This risk of acquisition
of infection appears to be great in health care workers,
especially in nurses and particularly during training, when
exposure is maximal. The experience of an exposure to
blood or body ﬂuids during the ﬁnal two years of study is
high. Nurses have an important role in disease control. It is
recommended that greater awareness is needed in society
about the ways of transmission of hepatitis B infection and
preventive measures should be improved. An increase in
awareness of the population of the risks of HBV infection
and of potential preventive measures will deﬁnitely improve
the control of HBV infection nationwide and will eventually
decrease the associated health care costs.
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Background: Almost 130 million Chinese people are
chronically infected with HBV. We need to pay more
attention to the chronic hepatitis B carriers in order to
administer them very well. So we study the inﬂuence
factors on liver inﬂammation and ﬁbrosis through the clinical
examination and liver biopsy.
Methods: Ultrasound guided needle biopsies were collected
from 158 chronic hepatitis B carriers. Chi square test was
used for statistics analysis.
Results: The average age of the 158 chronic hepatitis B
carriers is 31.7± 9.12 years old. 36 cases (22.8%) are G 2;
35 cases (22.2%) are S 2, 5 cases are G3 (among them
4 cases are S3, and 1 case is S4), 9 cases are S3, and one
is S4. 49 cases (31%) need treatments. There are signiﬁcant
differences on liver ﬁbrosis in gender, age and HBeAg. Among
the chronic hepatitis B carriers, the degree of liver ﬁbrosis is
more severe in that who is male (c2 = 4.17, P < 0.05). Though
the G 2 percentage of male exceed female, there have
no statistic difference (c2 = 3.26, P < 0.05). The carriers who
are older than 30 years are more severe than who are no
more than 30 years (c2 = 5.02, P < 0.05). The carriers who are
HBeAg negative are more severe than those who areHBeAg
positive on ﬁbrosis (HBVDNA is positive) (c2 = 4.52, P < 0.05).
There has no signiﬁcant difference on liver inﬂammation.
Conclusions: People consider that the chronic hepatitis B
carriers with normal ALT need not to be treated
traditionally. But we found that some carriers would develop
into cirrhosis and/or HCC. The state of illness aggravates
silently. So we can’t judge the illness by liver function
test, we should depend on the whole individually. There
are nearly 1/3 carriers with obvious inﬂammation and/or
ﬁbrosis, especially people who is male, older than 30 years
or whose HBeAg is negative (HBVDNA is positive), the degree
of ﬁbrosis is more severe. So we should pay more attention
to them, enhance the management, and treat them with
anti-virus and anti-ﬁbrosis therapy at necessary in order to
decrease the possibility of progressing to end-stage liver
diseases.
